Researchers analyzed clinical characteristics and survival in multiple myeloma (MM) among Hispanic patients compared to non-Hispanic white (NHW) and non-Hispanic Black (NHB) patients. The results were published in Clinical Lymphoma, Myeloma, & Leukemia.
Patients with MM from a single center between 2000 and 2017 were stratified by race: NHB (n=489), Hispanic (n=281), and NHW (n=169). A validation cohort was created using the Connect MM Registry, which contains data on patients newly diagnosed with MM.
Hispanic patients, compared to NHW patients, had a higher incidence of MM, as well as a younger median age at presentation (65 years vs. 70 years). The researchers also found that Hispanic patients were more likely to present with renal dysfunction. Compared to both NHW and NHB patients, Hispanic patients were more likely to have Revised International Staging System (R-ISS) stage I disease. Cytogenetics did not differ between patient groups. Multivariate analysis found that the only factors impacting survival were high-risk disease and response to first-line therapy.
“In this first and largest analysis of MM in Hispanics, we found that Hispanics present at a younger age, have a higher incidence of renal dysfunction, and have low R-ISS stage disease at presentation. With equal access to therapy, Hispanics have survival similar to NHW/NHB,” the researchers stated in their conclusion.